June 2010. Volume 6. Number 2

Botulinum toxin type A is the only therapy effective to reduce localized spasticity in children with cerebral palsy

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin JM, et al. Practice parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review). Neurology 2010;74:336-43
Reviewers: Ramos Lizana J1, Cuestas Montañés E2.
1Unidad de Neurología Pediátrica. Hospital Torrecárdenas. Almería. España.
2Servicio de Pediatría y Neonatología. Hospital Privado. Centro Formador. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba. Córdoba. Argentina.
Correspondence: Julio Ramos Lizana. Email: jramoslizana@telefonica.net
Reception date: 28/05/2010
Acceptance date: 17/06/2010
Publication date: 21/06/2010

Abstract

Authors’ conclusions: for localized/segmental spasticity that warrants treatment, botulism toxin type A should be offered as an effective and generally safe treatment. There are insufficient data to the use of phenol, alcohol or botulinum toxin type B. For generalized spasticity that warrants treatment, diazepam should be considered for short-term treatment, and tizanidine can be utilized. There are insufficient data to use dantrolene or baclofen (oral or intrathecal).

Reviewers’ commentary: apparently there is only evidence on efficacy and safety to use botulinum toxin type A in the treatment of localized or segmental spasticity in children with cerebral palsy.

How to cite this article

Ramos Lizana J, Cuestas Montañés E. La toxina botulínica tipo A es el único tratamiento probadamente efectivo para reducir la espasticidad localizada en niños con parálisis cerebral. Evid Pediatr. 2010;6:35.

AVC | Critically appraised articles

Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin JM, et al. Practice parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review). Neurology 2010;74:336-43
Reviewers: Ramos Lizana J1, Cuestas Montañés E2.
1Unidad de Neurología Pediátrica. Hospital Torrecárdenas. Almería. España.
2Servicio de Pediatría y Neonatología. Hospital Privado. Centro Formador. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba. Córdoba. Argentina.
Correspondence: Julio Ramos Lizana. Email: jramoslizana@telefonica.net
Reception date: 28/05/2010
Acceptance date: 17/06/2010
Publication date: 21/06/2010

How to cite this article

Ramos Lizana J, Cuestas Montañés E. La toxina botulínica tipo A es el único tratamiento probadamente efectivo para reducir la espasticidad localizada en niños con parálisis cerebral. Evid Pediatr. 2010;6:35.

References

  1. Shevell MI. Current understandings and challenges in the management of cerebral palsy. Minerva Pediatr. 2009;61:399-413.
  2. Patel DR, Soyode O. Pharmacologic interventions for reducing spasticity in cerebral palsy. Indian J Pediatr. 2005;72:869-72
21/06/2010

Linked Comment